Related by context. All words. (Click for frequent words.) 76 PARP inhibitor 75 proteasome inhibitors 73 anticancer agents 72 MEK inhibitors 72 molecularly targeted 71 HDAC inhibitors 70 EGFR inhibitors 70 PLX# 70 anticancer therapies 69 histone deacetylase inhibitors 69 integrase inhibitors 69 kinase inhibitors 68 olaparib 68 proteasome inhibitor 68 SERMs 68 tyrosine kinase inhibitor 68 tyrosine kinase inhibitors 67 Pertuzumab 67 protein kinase inhibitor 67 IGF 1R 67 hedgehog pathway 67 small molecule inhibitors 67 AMN# [001] 67 JAK3 67 anticancer therapy 67 chemotherapeutic agents 67 renin inhibitors 67 anti angiogenic drugs 67 Zolinza 67 chemotherapeutics 67 endostatin 67 anticancer drugs 66 gamma secretase inhibitors 66 mAbs 66 BRAF inhibitor 66 cediranib 66 antisense 66 CBLC# 66 multitargeted 66 Hsp# inhibitors 66 Olaparib 66 imatinib Gleevec 66 angiogenesis inhibitor 66 IAP inhibitors 66 pertuzumab 66 MMP inhibitors 65 BRAF inhibitors 65 Mipomersen 65 CETP inhibitors 65 VEGF receptor 65 NNRTIs 65 antisense oligonucleotide 65 taxanes 65 VEGF inhibitors 65 cilengitide 65 integrase inhibitor 65 Gleevec resistant 65 gamma secretase inhibitor 65 mTOR inhibitors 65 dasatinib Sprycel 65 insulin sensitizers 65 LY# [003] 65 chemotherapeutic drugs 65 PI3K inhibitors 65 abiraterone 65 Hedgehog pathway 65 enzastaurin 65 JAK inhibitors 65 AEG# 65 cancer immunotherapies 65 Imatinib 65 poly ADP ribose polymerase 64 IMA# 64 vascular disrupting agent 64 antisense oligonucleotides 64 biologic therapies 64 trastuzumab Herceptin 64 selective inhibitors 64 HCV protease inhibitors 64 chemotherapeutic agent 64 XmAb# 64 angiogenesis inhibitors 64 interferons 64 siRNA therapeutics 64 chemopreventive agent 64 Dapagliflozin 64 HDAC inhibition 64 Tyrima 64 vascular disrupting agents 64 DFMO 64 Monoclonal antibodies 64 humanized antibody 64 PKM2 64 anti angiogenic therapy 64 flavopiridol 64 selective inhibition 64 virotherapy 64 CCR5 antagonists 64 Smac mimetics 64 receptor tyrosine kinase inhibitor 64 WT1 64 Tarvacin 64 Akt1 64 FLT3 64 protease inhibitors 64 Symadex 64 gefitinib Iressa 64 OMP #M# 64 resolvins 63 metaglidasen 63 antisense drug 63 erlotinib Tarceva 63 Novartis Gleevec 63 iniparib 63 histone deacetylase HDAC inhibitors 63 SPC# [001] 63 Abiraterone 63 immunotoxin 63 Vandetanib 63 IGF IR 63 Crizotinib 63 Sym# 63 regorafenib 63 predictive biomarkers 63 enzyme inhibitors 63 OncoVEX GM CSF 63 anti angiogenic agents 63 Genentech Herceptin 63 immunomodulator 63 antisense drugs 63 Dasatinib 63 BAY #-# 63 MEK inhibitor 63 BCR ABL inhibitors 63 EGFR tyrosine kinase inhibitors 63 anticancer therapeutics 63 PXD# 63 ALK inhibitors 63 fulvestrant 63 Carfilzomib 63 kinase inhibitor 63 Maraviroc 63 epothilones 63 YONDELIS 63 Ceflatonin 63 anticancer agent 63 chemoresistance 63 Stat5 63 humanized monoclonal antibodies 63 erlotinib Tarceva ® 63 protein kinase inhibitors 63 teplizumab 63 oncolytic 63 vorinostat 63 Smac mimetic 63 Herceptin trastuzumab 63 Aurora kinase 62 anti angiogenic therapies 62 CDDO Im 62 LY# [002] 62 interferon IFN 62 nucleoside analogues 62 aromatase inhibitors 62 ixabepilone 62 p# inhibitors 62 Erlotinib 62 GSK3 62 BRAF mutation 62 BMS # 62 Azedra 62 TRV# [001] 62 STAT3 62 Nanobody ® 62 molecularly targeted therapies 62 antitumor 62 histone deacetylases 62 SARMs 62 Nanobodies ® 62 HDACi 62 delta isoform 62 antiviral therapies 62 Deforolimus 62 orally bioavailable 62 ErbB3 HER3 62 preclinical compounds 62 EGF receptor 62 JAK2 inhibitors 62 Nanobody 62 humanized monoclonal antibody 62 PARP inhibition 62 chemotherapeutic drug 62 panobinostat 62 Kinase inhibitors 62 A3 adenosine receptor 62 HIV protease inhibitors 62 NF kB pathway 62 TNFa 62 PPARγ 62 HSP# inhibitor 62 AMPK activators 62 EGFr 62 antiangiogenesis 62 ATL# [001] 62 Bortezomib 62 Sorafenib 62 lapatinib Tykerb 62 JAK2 62 preclinically 62 cytostatic 62 HDACs 62 serotonin receptor 62 CXCR4 receptor 62 CCX# 62 JAK2 inhibitor 62 T#I [002] 62 Onconase 62 fusion inhibitors 62 OncoVEX 62 bevacizumab Avastin 62 PI3K inhibitor 62 Phenoxodiol 62 CCR5 receptor antagonists 62 standard chemotherapy regimens 62 Xanafide 62 miR #a [002] 61 HCV protease 61 Tumor Necrosis Factor 61 obatoclax 61 Hsp# inhibition 61 immune modulators 61 Hycamtin 61 vemurafenib 61 antiviral compounds 61 nonsmall cell lung cancer 61 receptor antagonists 61 oral anticancer 61 GRN#L 61 direct thrombin inhibitors 61 polymerase inhibitors 61 anti mitotic 61 NKT cells 61 TriRima 61 CB1 antagonists 61 Temsirolimus 61 anti angiogenic 61 gastrointestinal stromal tumors 61 idarubicin 61 Gefitinib 61 chemotherapeutic 61 myeloproliferative disorders 61 cytotoxics 61 cathepsins 61 oxidative stress inducer 61 PKCi 61 Sphingomab 61 therapeutic monoclonal antibody 61 DXL# 61 EGFR 61 glioma cells 61 novel peptide 61 BRAF gene 61 Stapled Peptide 61 sorafenib Nexavar 61 Aliskiren 61 P#X# 61 HuLuc# 61 HER2 receptor 61 inhibit EGFR 61 DHFR 61 peptibody 61 therapies 61 Affinitak 61 EGFR pathway 61 Factor VIIa 61 Enzastaurin 61 myeloma cells 61 receptor agonists 61 alkylating agents 61 chemopreventive agents 61 druggable targets 61 telomerase inhibitors 61 gemcitabine Gemzar 61 sodium glucose cotransporter 61 PI3K 61 HGS ETR1 61 darapladib 61 CA4P 61 targeting CD# 61 monoclonal antibody therapies 61 JAK inhibitor 61 deacetylase inhibitors 61 siRNA therapeutic 61 pan HDAC inhibitor 61 TNFα 61 biologic therapy 61 CD# mAb 61 IDH1 61 ganetespib 61 Sutent sunitinib 61 TKIs 61 TLR8 61 immune modulator 61 CCR5 inhibitors 61 BRCA deficient 61 Vorinostat 61 vinca alkaloids 61 TLR9 agonists 61 Nanobodies 61 Neuvenge 61 LNP formulations 61 tubulin inhibitor 61 Pralatrexate 61 PI3 kinase 61 antisense compounds 61 histone methyltransferases HMTs 61 Squalamine 61 signal transduction inhibitor 61 trastuzumab DM1 60 EphA2 60 metastatic colorectal 60 engineered RAP peptides 60 UsiRNAs 60 anticancer compound 60 multi kinase inhibitor 60 PDGF receptor 60 oncolytic viruses 60 Bevacizumab 60 ErbB3 60 paclitaxel Taxol 60 EGFRvIII 60 myelofibrosis polycythemia vera 60 investigational therapies 60 CDK4 60 relapsed ovarian cancer 60 triphendiol 60 tumor hypoxia 60 imatinib resistance 60 visilizumab 60 Aplidin 60 BCR ABL 60 Panzem 60 aminoglycosides 60 taxane chemotherapy 60 K ras mutations 60 PPAR gamma 60 Perifosine 60 insulin sensitizing 60 metastatic renal cell carcinoma 60 Epothilones 60 imatinib Gleevec ® 60 macrolide antibiotics 60 bortezomib Velcade 60 Daclizumab 60 TNF inhibitors 60 Rituximab 60 Litx 60 biologic therapeutics 60 alkylating agent 60 Hedgehog signaling pathway 60 GW# [003] 60 LHRH agonists 60 OHR/AVR# 60 diagnostic biomarker 60 immunomodulatory 60 tyrosine kinase inhibitors TKIs 60 HDAC inhibitor 60 CCR2 60 photodynamic therapy 60 aptamers 60 epothilone 60 SGLT2 inhibitors 60 chemopreventive 60 GPCR targets 60 temsirolimus 60 Epratuzumab 60 VitiGam 60 therapeutic monoclonal antibodies 60 MUC1 60 Lisofylline 60 BRAF kinase 60 triterpenoids 60 SRT# [003] 60 hormonal therapies 60 therapeutic modality 60 atrasentan 60 radiation sensitizer 60 antiangiogenic 60 chemotherapies 60 farletuzumab 60 anthracyclines 60 selective kinase inhibitor 60 EGFR mutation 60 BNC# 60 androgen receptor 60 inhibitors 60 prostacyclin receptor 60 Velcade bortezomib 60 investigational humanized monoclonal antibody 60 nucleoside analogs 60 apoptotic pathway 60 Vidofludimus 60 eprotirome 60 interferon 60 tumor antigen 60 anti angiogenic agent 60 pDCs 60 immunotherapeutic agent 60 BiTE 60 CCR5 antagonist 60 PIK3CA 60 HCV polymerase inhibitors 60 peroxisome proliferator activated 60 Abiraterone acetate 60 melanoma tumors 60 cell signaling pathways 60 epithelial tumors 60 enzyme inhibitor 60 oral proteasome inhibitor 60 hypomethylating agents 60 AKT inhibitor 60 demethylating agents 60 small molecule activators 60 GGTase 60 PSN# [001] 60 Doxorubicin 60 selective estrogen receptor 60 highly selective endothelin 60 kinase inhibition 60 LHRH antagonists 60 PTP 1B 60 PDE4 inhibitor 60 talabostat 60 triptans 60 exon skipping 60 PI3K pathway 60 CTLA 4 60 TG# [003] 60 glucagon receptor 60 Bryostatin 60 Elesclomol 60 FGFR1 60 anticoagulant reversing agent 60 p# MAP kinase 60 NRG1 60 Ipilimumab 60 TAp# 60 HDAC 60 Bavituximab 60 crizotinib 60 T DM1 60 malignant pleural mesothelioma 60 2DG 60 depsipeptide 60 RGB # 60 c MET 60 PRT# 60 thalidomide Thalomid 60 differentiated thyroid 60 Amplimexon 60 riociguat 60 Raltegravir 60 androgen receptor AR 60 synthetic lethality 60 oncolytic virus 60 inhibitor RG# 60 dexpramipexole 60 potent inhibitors 60 adenosine receptor 60 otelixizumab 59 anticancer 59 taxol 59 proteases 59 CYT# potent vascular disrupting 59 Taxanes 59 isoform selective 59 small molecule inhibitor 59 cytoprotective 59 Gleevec imatinib 59 GDIR 59 induce apoptosis 59 infliximab Remicade 59 CCR9 antagonist 59 CD# antibody [001] 59 cancer therapeutics 59 Phylomer ® 59 Sorafenib Nexavar 59 neuroprotectant 59 brostallicin 59 potent inhibitor 59 selectively inhibit 59 FTIs 59 Traficet EN 59 entinostat 59 nucleosides 59 CDK inhibitors 59 calcineurin inhibitors 59 anti fibrotic 59 cetuximab Erbitux 59 anti TNF 59 cytotoxic 59 immunotherapies 59 histone deacetylase 59 Hedgehog inhibitor 59 JAK1 59 Syk 59 Therapeutic antibodies 59 hematological cancers 59 HDAC6 59 antibody mediated 59 Atrasentan 59 elotuzumab 59 tranilast 59 chemotherapeutic regimens 59 Lapatinib 59 tyrosine kinases 59 selective inhibitor 59 HGS# 59 Boceprevir 59 NEUGENE 59 Aviptadil 59 MAbs 59 DPP4 inhibitors 59 personalized immunotherapy 59 IAP inhibitor 59 glioblastoma 59 tumors 59 endoxifen 59 epigenetic therapeutics 59 endothelin receptor 59 mGluR2 NAM 59 Archexin 59 peptide antigens 59 calcineurin 59 c MYC 59 HIV integrase inhibitors 59 HQK 59 immunomodulators 59 HER2 positive metastatic breast 59 Tarvacin Anti Viral 59 Everolimus 59 ENMD # 59 ProMune 59 Wnt signaling pathway 59 immune modulation 59 lung adenocarcinoma 59 PGE2 59 ADAM# 59 GSK3B 59 rituximab Rituxan 59 TLR Therapeutics 59 BZL# 59 targeted radiotherapeutic 59 Anthracyclines 59 nucleoside analogue 59 nucleoside analog 59 Preclinical studies suggest 59 Debio 59 Gleevec imatinib mesylate 59 monoclonal antibody 59 lysosomal storage diseases 59 monoclonal antibody MAb 59 MDM2 59 TLR agonists 59 solid tumors 59 Panzem R NCD 59 Ataluren 59 TH# cells 59 Erbitux cetuximab 59 molecularly targeted therapy 59 tumor vasculature 59 immunosuppressive regimens 59 multidrug resistance 59 beta interferons 59 elvitegravir 59 Src inhibitors 59 metabolic enzymes 59 eIF 4E 59 Pemetrexed 59 oral antiviral 59 liposomal doxorubicin 59 MitoQ 59 Spiegelmers R 59 CXCR7 59 mGluR5 antagonist 59 HCV replication 59 liposomal formulation 59 CRTH2 59 immune modulating 59 EGFR HER 59 pomalidomide 59 histone deacetylase HDAC 59 antibody MAb 59 canagliflozin 59 superficial bladder cancer 59 RNAi therapeutic targeting 59 Ridaforolimus 59 5 HT2B receptor 59 antagomirs 59 inhibit metastasis 59 neuroendocrine cancers 59 CCR1 59 CD# antibodies 59 ALN TTR 59 EndoTAG TM -1 59 histone deacetylase HDAC inhibitor 59 tanespimycin 59 tumor subtypes 59 echinocandins 59 anti CD3 59 Bezielle 59 mutational status 59 adult mesenchymal stem 59 bevacizumab Avastin ® 59 Telaprevir 59 axitinib 59 proteasome inhibitor bortezomib 59 Onco TCS 59 Pim kinases 59 HER3 59 small molecule tyrosine 59 glioblastoma multiforme GBM 59 ZD# [001] 59 Cylene 59 cytotoxic agents 59 hormone gastrin 59 OXi# 59 Protease inhibitors 59 chemically modified siRNA 59 oncoprotein 59 INCB# [001] 59 TACI Ig 59 humanised monoclonal antibody 59 Tykerb 59 neratinib 59 Nexavar sorafenib 59 chemoprevention 59 aptamer 59 oral prodrug 59 immunotoxins 59 NNR Therapeutics 59 endocrine therapies 59 PKC# 59 Skp2 59 Talabostat 59 Blinatumomab 59 VDAs 59 EGFR TKIs 59 tipifarnib 59 interferon beta therapy 59 Zybrestat 59 CCR5 inhibitor 59 mTOR inhibitor 59 covalent drugs 59 ISIS # 59 amrubicin 59 EGFR receptor 59 TNF alpha inhibitors 59 histone deacetylase inhibitor 59 SOD1 59 mimetics 59 monoclonal antibodies 59 angiogenesis inhibition 59 FK# 59 CYC# 59 HIV protease 59 PI3K/mTOR 59 HER2 positive breast cancer 59 adipiplon 59 antiangiogenic agents 59 protein kinase C 59 Anti angiogenic 59 Abl 59 PPAR γ 59 daclizumab 59 Exemestane 59 decitabine 59 TREANDA 59 Annamycin 59 MGd 59 trans retinoic acid 59 oncogenic 59 synthetic retinoid 59 Curaxin 59 orally dosed 59 Kinases 59 breast cancer subtypes 59 pharmacological chaperone 59 medulloblastomas 59 Rituxan rituximab 58 gene fusions 58 oncoproteins 58 tumor suppressors 58 fusion inhibitor 58 druggable 58 ALK inhibitor 58 tafamidis 58 elesclomol 58 anti VEGF 58 RNA silencing 58 AP# [003] 58 PPARgamma 58 epigenetic enzymes 58 Fc fusion protein 58 mertansine 58 radionuclide therapy 58 FVIIa 58 Muraglitazar 58 nifurtimox 58 HER2 positive cancers 58 teriflunomide 58 tumor antigens 58 Trastuzumab 58 antimetabolite 58 sigma receptors 58 thymidylate synthase 58 antiproliferative effects 58 TRAIL receptor antibodies 58 vivo validation 58 histologies 58 M2 subunit 58 LNPs 58 Nexavar ® 58 Sirtuins 58 Interferon alpha 58 targeting PCSK9 58 Clusterin 58 CB2 receptor 58 endothelin receptor antagonists 58 NeuVax 58 Epidermal Growth Factor Receptor 58 elacytarabine 58 Neuradiab 58 molecular biomarkers 58 AQ4N 58 CTAP# Capsules 58 renin inhibitor 58 fibrotic disease 58 CCR3 58 activate SIRT1 58 antibody fragment 58 B Raf 58 SAR# [004] 58 fenretinide 58 PEG SN# 58 antisense RNA 58 cortisol receptor 58 AZD# 58 NK1R 58 OGG1 58 VEGFR2 58 molecular abnormalities 58 MAPK pathway 58 Tarvacin TM 58 cognitive enhancer 58 antithrombotic agents 58 Mitoxantrone 58 imetelstat 58 antimitotic 58 CGEN # 58 NFkB 58 FGFR 58 NovaBay Aganocide compounds 58 Shark cartilage 58 Laquinimod 58 gastrointestinal stromal tumors GIST 58 hematological indications 58 Elvitegravir 58 XL# XL# 58 epigenetic therapies 58 disease modifying 58 ERK pathway 58 antibody 58 Angiolix 58 anti angiogenesis 58 TBC# 58 #beta HSD1 58 immune stimulatory 58 prodrugs 58 Ganetespib 58 retinoids 58 cMET 58 pegfilgrastim 58 GRK2 58 GRP# 58 geldanamycin 58 figitumumab 58 SCH # 58 HCV protease inhibitor 58 transgenic rats 58 Anticalins 58 NADPH oxidase 58 Seliciclib 58 immunotherapeutic approaches 58 BiPar 58 TRIM5a 58 AV HALT 58 VA# [002] 58 fusion proteins 58 recurrent ovarian cancer 58 antisense inhibitors 58 MUC1 * 58 atacicept 58 Alemtuzumab 58 OMP #R# 58 Hsp# inhibitor 58 lupus nephritis 58 ImmunoVEX HSV2 58 GPCRs 58 orally administered inhibitor 58 Anacetrapib 58 oral antiplatelet 58 VEGFb 58 nucleotide analogues 58 hypoxia inducible factor 58 DNA methyltransferases 58 Tamibarotene 58 SGLT 2 58 IgG1 antibody 58 trabectedin 58 KRAS oncogene 58 inhibit viral replication 58 CDK inhibitor 58 cyclin D1 58 diagnostic biomarkers 58 neuroendocrine tumors 58 nutlin 58 FGFR2 58 EP #R 58 tyrosine kinase 58 castration resistant prostate cancer 58 anti androgen 58 ErbB2 58 investigational monoclonal antibody 58 Gleevec 58 immunoconjugate 58 modulates Akt 58 antimetastatic 58 estrogen receptor 58 biomarkers 58 Panitumumab 58 lung fibrosis 58 tumor cells 58 thyroid hormone receptor 58 IFN alpha 58 tarenflurbil 58 immunotherapeutic 58 Her2 58 myeloproliferative diseases 58 tumor suppressor genes 58 predictive biomarker 58 Intravenous CP 58 hES cells 58 mycophenolate mofetil 58 microtubule inhibitor 58 PROCHYMAL 58 IMC #B 58 lipid lowering therapies 58 miR #b [002] 58 HuMax CD# 58 Eribulin 58 miR #b [001] 58 p# inhibitor 58 Amrubicin 58 systemically administered 58 dAbs 58 DCVax R 58 immunosuppressive 58 antisense inhibition 58 chemoresistant 58 5 HT3 receptor 58 PI3 K 58 natriuretic peptide 58 sunitinib malate 58 ansamycin 58 NKG2D 58 reperfusion injury 58 MyVax R 58 Dalbavancin 58 Curaxin CBLC# 58 Pathway Inhibitor 58 CLL cells 58 multikinase inhibitor 58 TNF inhibitor 58 GAP #B# 58 Ixempra 58 metastatic RCC 58 IGF1R 58 bortezomib 58 Tarceva erlotinib 58 telomerase inhibitor 58 CXCR4 58 Ixabepilone 58 reverse transcriptase inhibitors 58 Pimavanserin 58 tyrosine kinase inhibitor TKI 58 anticancer compounds 58 transdifferentiation 58 clusterin 58 milatuzumab 58 Tofacitinib 58 Tocosol Paclitaxel 58 PSMA ADC 58 deforolimus 58 anti CD# antibodies 58 alpha folate receptor 58 OMAPRO 58 kinases 58 HSP# inhibitors 58 phosphate S1P 58 SERCA2a 58 ISF# 58 targeted antifolate 58 HER2 receptors 58 humanized antibodies 58 Sapacitabine 58 immunotherapeutics 58 generation antisense 58 nicotinic receptor 58 tremelimumab 58 Interferon 58 immunotherapy 58 haematological cancers 58 ASONEP 58 Aurora Kinase 58 cholinesterase inhibitors 58 NS4A 58 mda 7 58 PDE4 inhibitors 58 MAb 58 selective androgen receptor modulators 58 Six3 58 acetylcholinesterase AChE 58 vinca alkaloid 58 SU# [003] 58 SGLT2 58 kidney urologic 58 HSP# 58 LPA1 receptor 58 bendamustine 58 AEGR 58 Fludarabine 58 Rigel R# 58 ErbB2 positive 58 IMC A# 58 Tasimelteon 58 cholesteryl ester transfer 58 Apixaban 58 cyclophilin D 58 Omacetaxine 58 Davanat 58 taxane therapy 58 cisplatin chemotherapy 58 microRNA therapeutics 58 cellular pathways 58 mAb 58 neuroprotection 58 Factor Xa 58 Actilon 58 phenoxodiol 58 Reverset 58 MEK ERK 58 Cisplatin 57 potentiator 57 nilotinib Tasigna 57 Romidepsin 57 radioimmunotherapy 57 cyclin E 57 GIST tumors 57 IGFBP2 57 bispecific antibody 57 cabozantinib 57 thrombin receptor 57 Aflibercept 57 chronic lymphocytic leukemia CLL 57 CK2 57 factor Xa inhibitors 57 chemo resistant 57 HuMax EGFr 57 Voreloxin 57 PPAR alpha 57 Virulizin ® 57 alvespimycin 57 eflornithine 57 cytotoxic chemotherapy 57 JAK2 enzyme 57 glutamate receptors 57 TLR9 agonist 57 GSK# [002] 57 Janus Kinase 57 MEK inhibitor RDEA# 57 motesanib 57 melanocortin receptor agonists 57 ZK EPO 57 galanin 57 costimulation 57 TMEM#B 57 Doxil 57 ApoB SNALP 57 MLN#